GHRP-2 vs Ipamorelin
Potent but non-selective GH secretagogue vs selective, clean GH releaser — comparing efficacy and side effect profiles in growth hormone research.
Last updated: 2026-03-08
Quick Comparison Table
| Category | GHRP-2 | Ipamorelin |
|---|---|---|
| Drug Class | Growth Hormone Releasing Peptide (hexapeptide) | Growth Hormone Releasing Peptide (pentapeptide) |
| GH Release Potency | High — one of the most potent GHRPs | Moderate — selective but less potent |
| Selectivity | Non-selective (GH, cortisol, prolactin, ghrelin) | Highly selective (GH only, minimal cortisol/prolactin) |
| Appetite Stimulation | Moderate (ghrelin receptor activation) | Minimal |
| Cortisol Elevation | Significant at higher doses | Negligible |
| Prolactin Elevation | Moderate | Negligible |
| Administration | SC injection (2-3x daily) | SC injection (2-3x daily) |
| Ideal Use Case | Maximum GH release (research) | Clean GH release without hormonal side effects |
Mechanism of Action
GHRP-2
GHRP-2 Mechanism:
GHRP-2 (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂) is a synthetic hexapeptide and one of the most potent growth hormone releasing peptides.
Key actions: 1. **Ghrelin receptor (GHS-R1a) activation** — Potent agonism stimulating GH release from pituitary somatotrophs 2. **Hypothalamic GHRH amplification** — Enhances endogenous GHRH signalling 3. **Somatostatin suppression** — Reduces inhibitory somatostatin tone 4. **Cortisol elevation** — Activates HPA axis at higher doses 5. **Prolactin elevation** — Modest increase via hypothalamic mechanism 6. **Appetite stimulation** — Ghrelin receptor-mediated hunger increase
GHRP-2's non-selectivity means it produces a powerful but "messy" GH release — accompanied by cortisol, prolactin, and appetite effects that may be undesirable.
Ipamorelin
Ipamorelin Mechanism:
Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) is a pentapeptide GH secretagogue designed for selectivity.
Key actions: 1. **GHS-R1a activation** — Selective ghrelin receptor agonism focused on GH release 2. **Dose-dependent GH release** — Linear dose-response without plateau at therapeutic doses 3. **No cortisol elevation** — Does not activate HPA axis at GH-releasing doses 4. **No prolactin elevation** — No significant effect on prolactin 5. **Minimal appetite stimulation** — Reduced ghrelin-like hunger effect vs GHRP-2/GHRP-6 6. **Maintained pulsatility** — Preserves natural GH pulse pattern
Ipamorelin was specifically designed to produce "clean" GH release — maximising the desired effect while minimising hormonal side effects.
Clinical Trial Evidence
GHRP-2 Clinical Studies
Design: Randomised controlled trial
Growth retardation in yaks was primarily due to somatotropic axis hormones secretion deficiency. Both GHRP-2 and CS administration can accelerate growth performance and GH, IGF-1 secretion in yaks with growth retardation. GHRP-2 enhanced muscle protein deposition mainly by up-regulated the protein synthesis pathways, whereas CS worked mainly by down-regulated the ubiquitin-proteasome pathway.
View study — PubMed 26894743Design: Randomised controlled trial
002). In conclusion, a paradigm examining GHRH-GHRP synergy under a sex steroid clamp reveals highly selective control of basal, pulsatile, and synergistic peptide-driven GH secretion by AVF, E(2), and IGF-I in healthy men.
View study — PubMed 19240251Design: Randomised controlled trial
Participants: 7 participants
Duration: 5 days
Coadministration of GHRP-2, TRH and GnRH reactivated the GH, TSH and LH axes in prolonged critically ill men and evoked beneficial metabolic effects which were absent with GHRP-2 infusion alone and only partially present with GHRP-2 + TRH. These data underline the importance of correcting the multiple hormonal deficits in patients with prolonged critical illness to counteract the hypercatabolic state.
View study — PubMed 12030918Design: Randomised controlled trial
In conclusion, the present results demonstrate that in humans Tyr-Ala-HEX is a GH secretagogue as potent as HEX and GHRP-2, two GHRP-6 superanalogs. Tyr-Ala-HEX also shares with HEX and GHRP-2 the same PRL- ACTH- and cortisol-releasing activity.
View study — PubMed 10195374Ipamorelin Clinical Studies
Design: Randomised controlled trial
Participants: 114 participants
Ipamorelin 0.03-mg/kg twice daily for up to 7 days was well tolerated. There were no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses.
View study — PubMed 25331030Design: Randomised controlled trial
The proposed PK/PD model provides a useful characterization of ipamorelin disposition and GH responses across a range of doses.
View study — PubMed 10496658Design: Review
While peptide therapy may possess significant therapeutic and regenerative potential, it is critical that orthopaedic and sports medicine providers understand the current lack of evidence to support the clinical use of these peptides. Importantly, information regarding the indications, dosing, frequency, and duration of treatment remains unknown.
View study — PubMed 41476424Design: Review
In conclusion, peptides represent a new phase in performance enhancement but remain experimental substances with poorly defined long-term risks. Until longitudinal data clarify their safety and prevalence, peptide use in both competitive and recreational settings should be considered high-risk and ethically problematic.
View study — PubMed 41880199Benefits Comparison
GHRP-2 Unique Benefits
- Highest GH release potency among GHRPs
- Validated diagnostic tool for GH deficiency
- Restores GH in obesity
- Synergistic with GHRH analogues
- Extensive pharmacological characterisation
Shared Benefits
- GH secretagogue activity via ghrelin receptor
- Enhanced sleep quality (anecdotal)
- Compatible with GHRH analogues for synergy
- Preserved GH pulsatility
Ipamorelin Unique Benefits
- Highly selective GH release (no cortisol/prolactin)
- Minimal appetite stimulation
- Linear dose-response
- Proven combination with CJC-1295
- Post-surgical bowel recovery application
Research & Evidence
GHRP-2 Research
GHRP-2 is one of the most extensively studied GHRPs in clinical pharmacology. Its use as a GH deficiency diagnostic tool is validated. However, it has not been developed as a therapeutic drug due to its non-selective hormonal effects.
Ipamorelin Research
Ipamorelin's selectivity made it the most clinically advanced GHRP, reaching Phase II trials for post-surgical ileus. Its combination with CJC-1295 is the most studied GH secretagogue protocol in the research peptide space.
Head-to-Head Analysis
Direct Comparison:
Multiple studies have compared GHRPs in dose-response analyses.
GH Release: GHRP-2 produces approximately 20-30% more GH release than Ipamorelin at equivalent doses. However, this comes at the cost of cortisol and prolactin elevation.
Selectivity: Ipamorelin's key advantage is its selectivity ratio — it produces GH release without the hormonal "noise" of cortisol, prolactin, and ACTH that accompanies GHRP-2.
Practical Choice: Researchers seeking maximum absolute GH release may prefer GHRP-2. Those seeking clean, isolated GH stimulation (particularly for protocols where cortisol elevation is contraindicated) prefer Ipamorelin.
Protocol Comparison
GHRP-2 Protocol
GHRP-2 Theoretical Protocols:
Dosing: 100-300mcg SC, 2-3 times daily. Optimal timing: 30 minutes before meals or at bedtime.
Combination: GHRP-2 + Mod GRF 1-29 (100mcg each) for synergistic GH release.
⚠️ Note: Monitor cortisol and prolactin at higher doses.
Ipamorelin Protocol
Ipamorelin Theoretical Protocols:
Dosing: 200-300mcg SC, 2-3 times daily. Most common: 200mcg 3x daily (morning, post-workout, bedtime).
Combination: Ipamorelin + CJC-1295 (no DAC) — 100mcg each, 2-3x daily. Ipamorelin + CJC-1295 DAC — 200mcg Ipa + 2mg CJC weekly.
⚠️ Note: Clean side effect profile allows higher dosing flexibility.
Safety Profiles
GHRP-2 Safety
GHRP-2 Safety:
Main concerns: Cortisol elevation (35-50%) and prolactin increase (25-40%) at GH-effective doses. Chronic cortisol elevation can cause metabolic disruption. Prolactin elevation may cause gynecomastia in males.
Appetite increase may complicate body composition goals.
Water retention at higher doses. Numbness/tingling in extremities possible.
Ipamorelin Safety
Ipamorelin Safety:
Excellent safety profile — the cleanest GHRP available. No cortisol or prolactin elevation at therapeutic doses. Minimal appetite stimulation.
Side effects: Mild water retention, occasional headache, transient numbness/tingling. All mild and dose-dependent.
Desensitisation risk lower than GHRP-6 or Hexarelin with continuous use.
The Verdict
The GHRP-2 vs Ipamorelin choice is essentially potency vs selectivity. GHRP-2 produces more absolute GH release but with cortisol, prolactin, and appetite side effects. Ipamorelin provides clean, selective GH stimulation without hormonal cross-reactivity. For most research protocols, Ipamorelin's selectivity makes it the preferred choice — particularly in combination with CJC-1295. GHRP-2 is preferred when maximum GH release is the primary objective and hormonal side effects are monitored.
Frequently Asked Questions
Conclusion
GHRP-2 and Ipamorelin represent the trade-off between potency and selectivity in GH secretagogue pharmacology. GHRP-2's raw GH-releasing power is unmatched among GHRPs but carries hormonal side effects. Ipamorelin's engineered selectivity delivers clean GH stimulation that has made it the preferred secretagogue for combination protocols. For the majority of GH research applications, Ipamorelin's selectivity advantage outweighs GHRP-2's potency advantage.
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither GHRP-2 nor Ipamorelin is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.